Longboard Pharmaceuticals Analyst Ratings
Baird Maintains Outperform on Longboard Pharmaceuticals, Raises Price Target to $60
Longboard Pharmaceuticals Analyst Ratings
Optimistic Buy Rating for Longboard Pharmaceuticals Amid Breakthrough Therapy Designation and Strong Market Potential
Evercore ISI Raises Price Target on Longboard Pharmaceuticals to $80 From $57, Keeps Outperform Rating
Longboard Pharmaceuticals Analyst Ratings
Evercore ISI Raises Price Target on Longboard Pharmaceuticals to $57 From $44, Maintains Outperform Rating
Longboard Pharmaceuticals Analyst Ratings
B. Riley Raises Price Target on Longboard Pharmaceuticals to $36 From $30, Maintains Buy Rating
Wedbush Adjusts Longboard Pharmaceuticals Price Target to $42 From $34, Maintains Outperform Rating
Longboard Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Assertio Therapeutics (ASRT), Longboard Pharmaceuticals (LBPH) and Travere Therapeutics (TVTX)
Buy Rating Affirmed for Longboard Pharmaceuticals Amidst Positive Clinical Progress and Market Potential for Bexicaserin
Longboard Pharmaceuticals Analyst Ratings
Longboard Pharmaceuticals (LBPH) Receives a Buy From Wedbush
Longboard Pharmaceuticals Analyst Ratings
Buy Rating Affirmed on Longboard Pharmaceuticals With Promising Bexicaserin Developments and Regulatory Milestones Ahead
Longboard Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), Laboratory (LH) and Longboard Pharmaceuticals (LBPH)
Longboard Pharmaceuticals Analyst Ratings